Stanford Eye Laser Center
Palo Alto, California, 94303, United States
NCT Number: NCT02091934
The purpose of the study is to compare the results of PRKK surgery when using wavefront-guided excimer laser treatment compared to wavefront optimized excimer laser treatment in patients with nearsightedness with and without astigmatism
Looking for future studies?
Notify Me21 year–60 year
All sexes
Interventional
Not applicable
Palo Alto, California, 94303, United States
This is a research study comparing the outcomes of PRK surgery for nearsightedness when using the two different excimer laser technologies. Patients will have both eyes treated with the Alcon WaveLight Allegretto excimer laser. You will be one of 50 sighted patients at Stanford to undergo treatment in this clinical research trial. This will be a prospective, randomized, research study in which up to 100 consecutive eyes scheduled to undergo excimer laser photo refractive keratectomy (PRK) using one laser technology in the first eye and the second laser technology in the fellow eye for the correction of myopia (nearsightedness) with or without astigmatism will be enrolled. The choice of which eye receives the wavefront guided technology and which eye receives the wavefront-optimized technology will be randomized prior to enrollment. Randomization will be done according to a randomization schedule. You will not know which eye is being treated with which each technology. The randomization will determine only whether your right or left eye is treated with the wavefront guided technology. The other eye will be treated with wavefront-optimized laser technology. You have a fifty percent chance of having your left eye treated with custom wavefront guided technology as your right eye. Subjects will undergo bilateral (both eyes at once) PRK treatments using the Alcon WaveLight Allegretto excimer laser. All subjects will be followed for one year after the vision correction procedure. Subjects scheduled to undergo PRK for the correction of myopia (nearsightedness) with or without astigmatism will be screened for eligibility. Eligible subjects will be examined preoperatively to establish a baseline for ocular condition (the general health and glasses prescription of the eyes). Postoperatively, subjects will undergo an ophthalmic evaluation (complete eye examination) at regular intervals as specified in this protocol. Patients will complete questionnaires preoperatively and postoperatively evaluating quality of vision and quality of life. Retreatments (a second operation on the same eye for residual nearsightedness) will not be allowed during the first twelve months of this study. If you elect to undergo a retreatment of your PRK surgery prior to the 12-month post-operative visit, the retreated eye will be exited from the study as of the retreatment date.
Any significant new finding developed during the course of the research which may relate to the subject's willingness to continue participation will be provided to the subject or subject's representative in a timely manner.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Wavefront-guided PRK
Other names: Alcon Wavelight Eye-Q 400 wavefront-guided PRK
Wavefront-optimized PRK
Other names: Alcon Wavelight Eye-Q 400 wavefront-optimized PRK
Time frame: One year
Uncorrected visual acuity
Time frame: One year
Topographic analysis
Time frame: One year
Wavefront analysis
Time frame: One year
Patient Reported Outcomes Questionnaire
Time frame: One year
Corneal haze
Time frame: One year
Changes in best corrected 5 and 25% contrast visual acuity
Time frame: One year
Changes in best corrected visual acuity
Time frame: One year
Refractive predictability
Stanford University
Other
A Prospective, Randomized Comparison of Fellow Eyes Undergoing Wavefront-guided PRK Versus Wavefront-optimized PRK Using the Alcon Allegretto Eye-Q 400 Excimer Laser
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06873048
Astigmatism, Eye Diseases
Waterloo, Ontario, Canada
View Trial DetailsNCT04200898
Astigmatism, Eye Diseases
Zagreb, City of Zagreb, Croatia
View Trial DetailsNCT07291739
Astigmatism, Eye Diseases
Makati City, Philippines
View Trial DetailsNCT05740293
Astigmatism, Eye Diseases
Fayetteville, Arkansas, United States
View Trial Details